X
[{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LUMAKRAS\u2122 (Sotorasib) Combined With Vectibix\u00ae (Panitumumab) Showed Encouraging Efficacy And Safety In Patients With KRAS G12C-Mutated Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Head-To-Head Data Show Vectibix\u00ae (panitumumab) Demonstrated Superior Overall Survival Compared to Bevacizumab in Combination with Chemotherapy in Japanese Patients with Wild-Type Ras Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lumakras\u00ae (Sotorasib) Combined With Vectibix\u00ae (Panitumumab) Shows Confirmed 30% Objective Response Rate in Patients With KRAS G12C-mutated Metastatic Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lisata Completes Enrollment for CENDIFOX Pancreatic Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"}]
Find Clinical Drug Pipeline Developments & Deals for Panitumumab
Filters
Companies By Therapeutic Area
Details:
LSTA1 (certepetide) is an integrin alpha-V antagonist which is being evaluated in combination with folfirinox-based therapies for pancreatic, colon, and appendiceal cancers.
Lead Product(s):
Certepetide ,Panitumumab
Therapeutic Area: Oncology
Product Name: LSTA1
Highest Development Status: Phase I/ Phase II
Product Type: Peptide
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 13, 2024
Details:
Data showed that combining LUMAKRAS®/LUMYKRAS® (sotorasib) with Vectibix® (panitumumab), Amgen's monoclonal anti-epidermal growth factor receptor (anti-EGFR) antibody, demonstrated encouraging efficacy and safety.
Lead Product(s):
Sotorasib ,Panitumumab
Therapeutic Area: Oncology
Product Name: Lumakras
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
September 12, 2022
Details:
The results of trial showed that mFOLFOX6 + Vectibix (Panitumumab) combination provides a statistically significant improvement in OS over mFOLFOX6 + bevacizumab combination in patients with a left-sided primary tumor or regardless of tumor locations.
Lead Product(s):
Panitumumab ,Calcium Folinate ,Fluorouracil
Therapeutic Area: Oncology
Product Name: Vectibix
Highest Development Status: Approved
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 05, 2022
Details:
New data support initiation of Phase 3 trial of LUMAKRAS plus Vectibix in patients with 3L+ KRAS G12C-mutated advanced colorectal cancer (CRC). 9.7% response rate observed with LUMAKRAS monotherapy and highlight the importance of combination therapy in CodeBreaK 101 data.
Lead Product(s):
Sotorasib ,Panitumumab
Therapeutic Area: Oncology
Product Name: Lumakras
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
September 16, 2021